GT Biopharma (GTBP) AI Stock Analysis

• Market Cap: $7.02M
• Dividend Yield: N/A
• Average Volume (3M): 1.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.35
• Revenue Growth: N/A
• EPS Growth: 54.62%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.83
• Shares Outstanding: 10,636,135
• 10 Day Avg. Volume: 1,818,785
• 30 Day Avg. Volume: 1,629,462
• PEG Ratio: -0.02
• Price to Book (P/B): -3.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.45
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: $8.00
• Price Target Upside: 995.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $0.65 ▼(-10.96% Downside)

The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, and cash burn with reliance on external funding). Technicals are a partial offset with an improving trend, but momentum appears stretched, and valuation support is limited due to negative earnings and no dividend.

Positive Factors

Proprietary TriKE/TetraKE NK‑cell engager platforms

GT Biopharma’s TriKE/TetraKE platform is a durable, platform-level asset that can be applied across hematologic and solid tumor indications. Platform-based pipelines increase optionality and potential multiple product opportunities, lowering single-product binary risk if clinical validation is achieved.

No reported debt on balance sheet

Zero reported debt materially reduces fixed financing obligations and lowers short-term insolvency risk. For a development-stage biotech, low leverage preserves strategic flexibility to time capital raises and prioritize R&D spend without servicing interest, a durable financial advantage.

Improving loss and cash‑burn trend

Sequential improvement in net loss and operating cash burn indicates better cost discipline or program prioritization, extending runway relative to prior years. If sustained, this trend reduces near-term financing pressure and supports longer-term clinical development continuity.

Negative Factors

Pre‑revenue company with ongoing net losses

Being pre-revenue means GTB’s economics depend entirely on successful clinical outcomes and future commercialization. Persistent losses make the business model unproven commercially and create long-term uncertainty until products generate sustainable revenue streams.

Negative operating cash flow requires external funding

Sustained negative operating cash flow is structural for development-stage biotech and necessitates external financing. Reliance on capital markets increases dilution risk and can constrain strategic choices if market access tightens, a persistent vulnerability for long-term capital planning.

Thin, volatile equity base increases dilution risk

A recently repaired but small equity base leaves limited capital cushion against continued losses. With ongoing burn and no revenue, the company is likely to need additional raises, which can dilute shareholders and limit ability to fund multiple programs concurrently over the medium term.

GT Biopharma Business Overview & Revenue Model

Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

How the Company Makes Money

GT Biopharma makes money primarily through the development and commercialization of its proprietary TriKE platform, which is designed to create targeted cancer therapies. The company generates revenue through partnerships, licensing agreements, and potential future sales of its product candidates upon regulatory approval. Key revenue streams include milestone payments, royalties on sales, and collaboration agreements with larger pharmaceutical companies. Additionally, GT Biopharma may receive funding from government grants and research collaborations to support its clinical trials and research initiatives.

GT Biopharma Financial Statement Overview

Summary

Development-stage profile with zero revenue, ongoing net losses, and persistent cash burn. Positives include no reported debt and some improvement in losses/cash burn with equity turning positive in TTM, but funding dependence and dilution risk remain key overhangs.

Income Statement

GT Biopharma is still pre-revenue (zero revenue across annual periods and TTM (Trailing-Twelve-Months)), so losses are the defining feature of the income statement. Net losses remain substantial (TTM net loss of about $9.1M vs. ~$13.2M in 2024), showing some improvement versus last year but still indicating an unprofitable operating model. Profitability is not yet established, and results are highly dependent on continued funding rather than operating performance.

Balance Sheet

Leverage appears low with total debt reported at $0 in 2024 and TTM (Trailing-Twelve-Months), which reduces bankruptcy risk from debt service. However, equity has been volatile and thin relative to the business needs: stockholders’ equity moved from negative in 2024 (-$1.7M) to positive in TTM (~$3.0M), suggesting recapitalization or balance-sheet repair but not yet a strong capital base. With ongoing losses, the balance sheet remains sensitive to future capital raises and dilution risk.

Cash Flow

Cash generation is negative and consistent with a development-stage biotech: operating cash flow was about -$11.4M in TTM (Trailing-Twelve-Months) and -$12.9M in 2024, implying continued cash burn. Free cash flow is also negative (matching operating cash flow), though the burn rate has improved versus 2024 and is better than earlier years like 2021–2022. The key weakness is the need for external financing to sustain operations given the lack of revenue.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-9.10M	-13.16M	5.98M	-20.96M	-57.48M	-24.97M
Net Income	-9.10M	-13.16M	-7.60M	-20.88M	-58.01M	-28.30M
Balance Sheet
Total Assets	4.32M	4.23M	14.11M	16.74M	32.17M	5.66M
Cash, Cash Equivalents and Short-Term Investments	2.62M	3.95M	13.97M	16.51M	31.98M	5.30M
Total Debt	0.00	0.00	58.00K	174.00K	31.00K	26.33M
Total Liabilities	1.32M	5.90M	6.63M	5.00M	10.26M	35.09M
Stockholders Equity	3.00M	-1.67M	7.48M	11.73M	21.91M	-29.26M
Cash Flow
Free Cash Flow	-11.36M	-12.90M	-8.85M	-15.22M	-15.61M	-7.26M
Operating Cash Flow	-11.36M	-12.90M	-8.85M	-15.22M	-15.61M	-7.26M
Investing Cash Flow	1.00K	12.89M	-2.01M	12.14M	-23.04M	0.00
Financing Cash Flow	7.47M	2.98M	6.27M	-224.00K	42.32M	12.53M

GT Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.72, and below the 200-day MA of 1.46, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.65 is Neutral, neither overbought nor oversold. The STOCH value of 17.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GTBP.

GT Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GTBP	47 Neutral	$7.02M	-0.19	-356.99%	―	―	54.62%
DRMA	47 Neutral	$6.38M	-0.11	-203.36%	―	―	90.53%
TOVX	45 Neutral	$6.42M	-0.03	-166.96%	―	―	83.25%
REVB	45 Neutral	$3.22M	-0.02	-118.88%	―	―	96.26%
AZTR	45 Neutral	$2.63M	-0.04	-215.04%	―	-100.00%	93.82%